103 GHP Healthcare & Pharma Awards 2023 Bringing any new pharmaceutical product to market can be difficult, but in the case of the global cell and gene therapy market the challenges are even greater.With the high cost of therapies and limited patient data it can be difficult to demonstrate the true value of a potential new therapy. However, with the collaboration and support of AscellaHealth, specialty pharmaceutical manufacturers can navigate the route to market in a more cost-effective, patient-led and successful way. Best Global Specialty Pharmacy & Healthcare Services Organization 2023 A key challenge facing companies developing specialty and rare disease therapies is the substantial upfront cost, which can reach millions of pounds – with no cost-minimisation or curative guarantees. This is often the key factor preventing patients from gaining access to potentially life-saving treatment. Due to the nature of rare/orphan diseases, there is also minimal patient data available to accurately establish the effectiveness of treatments to gain regulatory approval or much-needed funding. Both factors combine to make gaining market access a time-consuming and problematic process. AscellaHealth is committed to helping life sciences organisations overcome these challenges and identify opportunities to enhance revenue, by providing a consultative approach designed to streamline commercialisation and optimise outcomes. It is a single-source partner for patients, life sciences manufacturers, payers and providers – providing pre-commercialisation support, market access expertise, supply chain logistics, distribution, fulfilment and unique pharmaceutical financial solutions to increase affordability of treatments. All designed to help bring novel pharmaceutical products to market, optimise cost savings, enhance clinical outcomes and optimise the patient journey. One example of how AscellaHealth leads the way in providing innovative solutions to improve the affordability and accessibility of life-changing therapies, is its market-leading pharmaceutical financial programme, Pharma FlexFund™. Developed by AscellaHealth to enable industry stakeholders to fund expensive treatments for rare and complex diseases, Pharma FlexFund™ is a pharmaceutical financial solution that brings fundamental change to the specialty pharmacy sectors. Treatments for rare diseases typically cost millions of pounds to develop. With Pharma FlexFund™, NHS and private healthcare organisations can now offset costs for therapies over an extended period of time. Pharma FlexFund™ benefits both hospitals and patients as it converts the high-upfront cost of therapies into custom payment terms extended over time – breaking down the cost into more affordable terms. Increased flexibility and assurances combine to broaden patient accessibility to curative and life-enhancing therapies. Drug manufacturers also gain advantage from the programme through enhanced competitive profile and brand loyalty, expanded market and accelerated commercialisation, greater control over cash flows and revenue recognition, and increased development pathways that can be utilised for more prevalent diseases. Ultimately, the financial solution improves patient access to potentially curative treatments and enhance outcomes, while enabling hospitals to retain more cash to spend in other areas. AscellaHealth’s Pharma FlexFund™ is revolutionising the rare disease and cell and gene therapy sectors by providing patients with access to novel treatments. As a global specialty pharmacy and healthcare services provider, AscellaHealth is dedicated to advancing life sciences globally, with locations in the United States and Europe. The organisation plans to continue on a high growth trajectory via organic growth and additional acquisitions. AscellaHealth continues to take advantage of worldwide opportunities to collaborate with pharmaceutical/biotech manufacturers and other industry stakeholders to help bring novel products to market, optimise cost savings for clients, and enhance clinical outcomes for specialty and rare disease patients. Contact: Darcey McDermott, Chief Marketing & Communications Officer Company: AscellaHealth Web Address: www.ascellahealth.com Email : [email protected] Aug23265 AscellaHealth Leadership Left to Right: John Campolongo - Chief Operating Officer - Craig Caceci - Managing Director EU/ UK - Dea Belazi – President & CEO
RkJQdWJsaXNoZXIy MTUyMDQwMA==